The EU Health Technology Assessment Regulation (HTAR) is reshaping how medicines reach European patients. Its centrepiece, the Joint Clinical Assessment (JCA), introduces a single EU-level clinical assessment that runs in parallel with the EMA marketing-authorisation process — changing both the evidence you need and when you need it.
The phased timeline
| From | Scope |
|---|---|
| January 2025 | New oncology medicines and advanced therapy medicinal products (ATMPs) |
| 2026 | Selected high-risk medical devices |
| January 2028 | Orphan medicinal products |
| 2030 | All centrally authorised medicinal products |
For cell & gene therapy developers, the implication is immediate: as ATMPs, your products are already in scope. For orphan drugs more broadly, 2028 is closer than it appears once you account for development timelines.
What changes for the evidence base
The JCA assesses relative clinical effectiveness against a set of PICO (Population, Intervention, Comparator, Outcome) questions defined across member states. Because different countries may favour different comparators, a single trial design must satisfy a wider, sometimes divergent, set of evidence needs. Engaging early through Joint Scientific Consultation (JSC) is the practical way to de-risk this.
What stays national
Crucially, the JCA covers the clinical assessment only. Pricing and reimbursement decisions remain national — G-BA AMNOG in Germany, HAS in France, AIFA in Italy, NICE in the UK (outside the EU framework). The JCA informs these processes; it does not replace them.
The practical takeaway for emerging biotechs
The parallel nature of the JCA means European evidence planning can no longer wait until after a US launch. Comparator selection, real-world evidence strategy and HTA readiness need to be on the roadmap at late Phase 2 — which is precisely why a structured, gated European plan matters.